Safety of Ultra-rush Schedule of Subcutaneous Allergen Immunotherapy With House Dust Mite Extract Conducted in an Outpatient Clinic in Patients With Atopic Dermatitis and Allergic Rhinitis.

CONCLUSIONS: UR-SCIT with tyrosine-adsorbed HDM extract conducted in an outpatient clinic was tolerable in patients with AD and AR. UR-SCIT can be a useful method to start a SCIT in patients with AD and AR. PMID: 31552719 [PubMed]
Source: Allergy, Asthma and Immunology Research - Category: Allergy & Immunology Tags: Allergy Asthma Immunol Res Source Type: research

Related Links:

AbstractPurpose of ReviewIn light of the recent advancements in atopic dermatitis treatment, this review aims to summarize the utility and efficacy of allergy immunotherapy in atopic dermatitis patients. We examine its mechanism, pathophysiology, cost-efficacy, and current guidelines for clinical practice.Recent FindingsThe literature supports the use of allergy immunotherapy in atopic conditions such as allergic rhinitis and asthma but insufficient evidence exists to suggest its efficacy in atopic dermatitis. The use of allergy immunotherapy has been shown to provide long-term cost savings in both the USA and the European...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
AbstractPurpose of reviewThe aim of this paper is to review and summarise the current knowledge of prevention of house dust mite (HDM)-induced allergic rhinitis (AR).Recent findingsAR can be either classified as seasonal/intermittent (for example hay fever occurring summer and autumn) or perennial/persistent (occurring throughout the year). The commonest trigger for seasonal AR is pollen whereas HDMs are the key allergic trigger for perennial AR. HDMs are a recognised indoor allergen that is crucial in the development of AR, asthma, and atopic dermatitis.SummaryPreventive strategies have gained acceptance for the managemen...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
Abstract PURPOSE: Allergen-specific immunotherapy (AIT) is the only curative treatment for allergic diseases, but a few allergic patients receive AIT. In this multicenter cross-sectional study, we aimed to explore patient and physician perspectives on AIT through a questionnaire survey. MATERIALS AND METHODS: Allergic patients who received subcutaneous immunotherapy for at least 1 year were asked to answer a questionnaire developed by an expert panel of allergen and immunotherapy workgroup in Korea. RESULTS: A total of 267 patients (adults, 60.3%) with allergic rhinitis (91.4%), asthma (42.7%), or atopic...
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
Currently, the only systemic treatment of allergic diseases is allergen specific immunotherapy (ASIT). The therapy duration may take up to 3 years and in some cases ASIT may not be effective. The elevated levels of allergen-specific IgG4 (sIgG4) is associated with the effectiveness of the treatment.The aim of the study was to detect the differences of sIgG4 levels among allergic patients and patients during ASIT.1000 samples from patients aged 6 months to 17 years from the Moscow region who were suspected of having allergic diseases such as pollinosis, allergic rhinitis, atopic dermatitis and bronchial asthma were included...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Allergy and immunology Source Type: research
Both subcutaneous and sublingual allergy immunotherapy (SCIT and SLIT, respectively) for inhalant allergens have proven efficacy for allergic rhinitis and allergic asthma, with limited support for efficacy in selected patients with atopic dermatitis.1 Both SCIT and SLIT have been shown to modify the immunologic defect underlying the allergic respiratory diseases,2 an effect that is clinically manifest by suppression of new sensitization in monosensitized patients, reduction in the development of asthma in those only having allergic rhinitis, and persistence of clinical improvement for years after an adequate course of treatment.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Perspective Source Type: research
AbstractPurpose of ReviewThe progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis and asthma in children, adolescents, and adults defines the allergy march. Allergen immunotherapy is the only causal treatment altering the immunological mechanism underlying the allergic diseases. The sublingual administration route is more acceptable than the subcutaneous one in pediatric age.Recent FindingsSeveral studies show the efficacy and safety profile of sublingual immunotherapy (SLIT) for the treatment of respiratory allergy diseases, but few data are available on its effect of primary and secondar...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
Publication date: Available online 1 February 2018 Source:The Journal of Allergy and Clinical Immunology: In Practice Author(s): Michael Schatz, Scott H. Sicherer, Robert S. Zeiger An impressive number of clinically impactful studies and reviews were published in The Journal of Allergy and Clinical Immunology: In Practice in 2017. As a service to our readers, the editors provide this Year in Review article to highlight and contextualize the advances published over the past year. We include information from articles on asthma, allergic rhinitis, rhinosinusitis, immunotherapy, atopic dermatitis, contact dermatitis, food all...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Subcutaneous allergen immunotherapy (SCIT) is efficacious in patients with allergic rhinitis, asthma and atopic dermatitis. However, SCIT can be associated with systemic reactions (SR). Our aim was to identify risk factors for SR to SCIT in our population.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Many patients with eosinophilic esophagitis (EoE) have concomitant atopic disorders such as allergic rhinitis, asthma, and atopic dermatitis which can be treated with subcutaneous allergen immunotherapy (IT). However, there are limited data describing the role of IT in the treatment of EoE.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
This article reflects the most pertinent aspects of the guidelines. It also provides a short summary of a new allergy diagnostic test available in SA, the multiplexmicroarray chip, known as the immuno-solid-phase allergen chip (ISAC) test. It provides component-resolved allergy testing for special circumstances and complex allergic problems and is certainly not required as a screening allergy test. Finally, this article gives an update on allergen immunotherapy - some patients with allergic conditions may benefit from immunotherapy. In SA, some forms of immunotherapy for allergic rhinitis and mild asthm...
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Dermatitis | Dermatology | Hay Fever | Immunotherapy